• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Adv . Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor

tetano

Editor, Senior Moderator
Sci Adv


. 2023 Jul 28;9(30):eade3470.
doi: 10.1126/sciadv.ade3470. Epub 2023 Jul 26. Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor

Wan Ni Chia[SUP] 1 [/SUP], Chee Wah Tan[SUP] 1 [/SUP], Aaron Wai Kit Tan[SUP] 1 [/SUP], Barnaby Young[SUP] 2 3 4 [/SUP], Tyler N Starr[SUP] 5 6 [/SUP], Ester Lopez[SUP] 7 [/SUP], Guntur Fibriansah[SUP] 1 [/SUP], Jennifer Barr[SUP] 8 [/SUP], Samuel Cheng[SUP] 9 [/SUP], Aileen Ying-Yan Yeoh[SUP] 1 [/SUP], Wee Chee Yap[SUP] 1 [/SUP], Beng Lee Lim[SUP] 1 [/SUP], Thiam-Seng Ng[SUP] 1 [/SUP], Wan Rong Sia[SUP] 1 [/SUP], Feng Zhu[SUP] 1 [/SUP], Shiwei Chen[SUP] 1 [/SUP], Jinyan Zhang[SUP] 1 [/SUP], Madeline Sheng Si Kwek[SUP] 1 [/SUP], Allison J Greaney[SUP] 5 [/SUP], Mark Chen[SUP] 2 3 [/SUP], Gough G Au[SUP] 8 [/SUP], Prasad N Paradkar[SUP] 8 [/SUP], Malik Peiris[SUP] 9 10 11 [/SUP], Amy W Chung[SUP] 7 [/SUP], Jesse D Bloom[SUP] 5 [/SUP], David Lye[SUP] 2 3 4 12 [/SUP], Sheemei Lok[SUP] 1 [/SUP], Lin-Fa Wang[SUP] 1 13 [/SUP]



Affiliations
Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern such as Omicron hampered efforts in controlling the ongoing coronavirus disease 2019 pandemic due to their ability to escape neutralizing antibodies induced by vaccination or prior infection, highlighting the need to develop broad-spectrum vaccines and therapeutics. Most human monoclonal antibodies (mAbs) reported to date have not demonstrated true pan-sarbecovirus neutralizing breadth especially against animal sarbecoviruses. Here, we report the isolation and characterization of highly potent mAbs targeting the receptor binding domain (RBD) of huACE2-dependent sarbecovirus from a SARS-CoV survivor vaccinated with BNT162b2. Among the six mAbs identified, one (E7) showed better huACE2-dependent sarbecovirus neutralizing potency and breadth than any other mAbs reported to date. Mutagenesis and cryo-electron microscopy studies indicate that these mAbs have a unique RBD contact footprint and that E7 binds to a quaternary structure-dependent epitope.


 
Back
Top Bottom